A Prospective Evaluation of Radiofrequency Ablation in the Treatment of Relapsed Graves' Disease.
Launched by THE UNIVERSITY OF HONG KONG · May 13, 2024
Trial Information
Current as of June 30, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment option called radiofrequency ablation (RFA) for patients with relapsed Graves' disease, a condition where the thyroid gland is overactive and can cause various health issues. RFA is a minimally invasive procedure that uses heat to target and treat the affected thyroid tissue without the need for surgery, which means there are no scarring and patients can go home the same day. The goal is to see how safe and effective RFA is compared to existing treatments.
To participate in this trial, individuals must be over 18 years old and have experienced a return of Graves' disease symptoms despite receiving treatment for at least 18 months. They should not have certain conditions that could complicate the procedure, such as previous neck surgeries or severe eye problems linked to Graves' disease. Those who qualify will undergo a procedure guided by ultrasound, where a small device will be used to apply heat directly to the thyroid tissue. This trial is still actively recruiting participants, but it's important to note that it is not looking for new recruits at this moment. If you or a loved one are considering this option, it could be a chance to explore a new approach to managing Graves' disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (a) age older than 18 years,
- • (b) relapsed Graves' disease despite an adequate ATD treatment for 18 months or more and
- • (c) absence of vocal cord immobility.
- Exclusion Criteria:
- • (a) patients who prefer or indicated for surgery,
- • (b) head and/or neck disease preventing hyperextension of the neck,
- • (c) history of thyroid cancer or other malignant tumors in the neck region,
- • (d) history of neck irradiation,
- • (e) moderate to severe Graves' ophthalmopatty,
- • (f) large compressive goiter
- • (g) pregnancy or lactation, and
- • (h) any contraindication related to intravenous moderate sedation.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Matrix, Man Him Fung, MBBS
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported